(Total Views: 559)
Posted On: 05/13/2020 6:21:45 PM
Post# of 155816
Sunny,
Thank you for all the hard work you put into this report.
I couple of observations:
1) There is usually a large institutional raise concomitant with an up-listing and may happen at a much lower price point, unless CYDY receives a large non-dilutive funding shortly.
2) I would consider modeling NASH related diseases separately given the amount of work that already went into this and its fairly large market that is growing rapidly.
3) In this type of modeling it is not uncommon to layer over these projections probabilities of success. For example, for HIV combo I would guess probability of success is > 95%, for HIV mono > 90%, etc., based on the amount of research and stages of the trials.
Thank you again for your contributions to this board.
Thank you for all the hard work you put into this report.
I couple of observations:
1) There is usually a large institutional raise concomitant with an up-listing and may happen at a much lower price point, unless CYDY receives a large non-dilutive funding shortly.
2) I would consider modeling NASH related diseases separately given the amount of work that already went into this and its fairly large market that is growing rapidly.
3) In this type of modeling it is not uncommon to layer over these projections probabilities of success. For example, for HIV combo I would guess probability of success is > 95%, for HIV mono > 90%, etc., based on the amount of research and stages of the trials.
Thank you again for your contributions to this board.
(2)
(0)
